Rita Cristina Myriam Intravaia

Dr. Rita Cristina Myriam Intravaia

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2023 in European Heart Journal Supplements
Verified
Journal Article
Open access
PDF file
SFStefania Angela Di Fusco
Stefania Angela Di Fusco
AAAlessandro Alonzo
Alessandro Alonzo
AAAlberto Aimo
Alberto Aimo
AMAndrea Matteucci
Andrea Matteucci
RIRita Cristina Myriam Intravaia
Rita Cristina Myriam Intravaia
FCFurio Colivicchi
Furio Colivicchi
In the growing therapeutic armamentarium for heart failure (HF) management, vericiguat represents an innovative therapeutic option. The biological target of this drug is different from that of other drugs for HF. Indeed, vericiguat does not inhibit neuro-hormonal systems overactivated in HF or sodium–glucose co-transporter 2 but stimulates the biological pathway of nitric oxide and cyclic guanosine monophosphate, which is impaired in patients with HF. Vericiguat has recently been approved by international and national regulatory authorities for the treatment of patients with HF and reduced ejection fraction who are symptomatic despite optimal medical therapy and have worsening HF. This ANMCO position paper summarises key aspects of vericiguat mechanism of action and provides a review of available clinical evidence. Furthermore, this document reports use indications based on international guideline recommendations and local regulatory authority approval at the time of writing.

7 August 2023 in The International Journal of Cardiovascular Imaging
Verified
Journal Article
Closed access
PDF file
DLDaniela Di Lisi
Daniela Di Lisi
GMGirolamo Manno
Girolamo Manno
CMCristina Madaudo
Cristina Madaudo
CFClarissa Filorizzo
Clarissa Filorizzo
RIRita Cristina Myriam Intravaia
Rita Cristina Myriam Intravaia
GNGiuseppina Novo
Giuseppina Novo

13 October 2025 in Nutrition, Metabolism and Cardiovascular Diseases
Verified
Journal Article
Open access
RIRita Cristina Myriam Intravaia
Rita Cristina Myriam Intravaia
CTChiara Tognola
Chiara Tognola
AMALESSANDRO MALOBERTI
ALESSANDRO MALOBERTI
FBFilippo Brucato
Filippo Brucato
ECElisa Campione
Elisa Campione
PTPierluigi Temporelli
Pierluigi Temporelli
Low-grade inflammation is a key driver of the pathogenesis and complications of acute coronary syndromes (ACS), playing a central role in plaque development and destabilization. This systematic review provides a comprehensive analysis of evidence from observational studies and clinical trials, exploring the implications of inflammatory pathways in ACS patients. We systematically reviewed inflammatory biomarkers evaluated in ACS patients (white blood cell count, fibrinogen, C-reactive protein, tumor necrosis factor - α, CD40-ligand, interleukin-6, interleukin-18, osteoprotegerin, calprotectin, mean platelet volume, neutrophil percentage albumin ratio, neutrophil-lymphocyte ratio, systemic inflammatory index, platelet-lymphocyte ratio and C-reactive protein/albumin ratio). Furthermore, we reviewed also the already published (mainly on colchicine) and the on-going trial on anti-inflammatory therapies in ACS patients. This review highlights the emerging role of inflammation in evaluating residual cardiovascular risk and focus on possible therapies that could modulate inflammation and improve outcomes in ACS patients particularly in the one at higher risk (i.e. extreme CV risk).

15 July 2025 in International Journal of Cardiology
Verified
Journal Article
Open access
CTChiara Tognola
Chiara Tognola
DBDavide Bernasconi
Davide Bernasconi
RIRita Cristina Myriam Intravaia
Rita Cristina Myriam Intravaia
GBGiulia Brioschi
Giulia Brioschi
GTGiorgio Toscani
Giorgio Toscani
AMALESSANDRO MALOBERTI
ALESSANDRO MALOBERTI
Prevalence of hypertriglyceridemia in patients with Acute and Chronic Coronary Syndrome (ACS and CCS, respectively) in the current era of Low-Density Lipoprotein Cholesterol (LDL-C) targets remains unknown. This study aimed to evaluate the prevalence of triglyceride (TG) levels above 150 mg/dL in ACS and CCS patients enrolled in a Cardiac Rehabilitation (CR) program and to explore its association with extreme cardiovascular (CV) risk. We included 905 ACS/CCS patients who participated in the CR program at Niguarda Hospital (Milan) between January 1, 2012, and March 28, 2024. Data on demographic, clinical, and laboratory variables were collected. Extreme CV risk was defined as the occurrence of a CV event within two years or the presence of peripheral artery disease or multivessel coronary involvement. TG levels significantly decreased during the CR period (median 116.5, I-III quartiles 87-115 vs. 100, 80-133 mg/dL, p < 0.001), as did LDL-C levels (106.8 ± 39.3 vs. 64.4 ± 24.9 mg/dL, p < 0.001). At the end of CR, 17.6 % of patients had TG levels ≥150 mg/dL (15.0 % among those who reached the LDL-C target). In multivariable analysis, each 10 mg/dL increase in TG was associated with a 4.6 % increased risk of extreme CV risk (OR 1.046; 95 %CI 1.007-1.085; p = 0.019). Additionally, hypertriglyceridemia (TG >150 mg/dL) increased the risk of extreme CV risk by 81.5 % (OR 1.815; 95 %CI 1.096-3.007; p = 0.021). Despite high-intensity statin therapy and low LDL-C targets, a significant proportion of patients in CR still exhibited elevated TG levels. Both TG levels and hypertriglyceridemia were strongly associated with the presence of extreme CV risk.

30 November 2023 in High Blood Pressure & Cardiovascular Prevention
Verified
Journal Article
Open access
PDF file
AMALESSANDRO MALOBERTI
ALESSANDRO MALOBERTI
RIRita Cristina Myriam Intravaia
Rita Cristina Myriam Intravaia
CMCostantino Mancusi
Costantino Mancusi
ACArturo Cesaro
Arturo Cesaro
EGEnrica Golia
Enrica Golia
CGCristina Giannattasio
Cristina Giannattasio
Introduction Despite significant improvement in secondary CardioVascular (CV) preventive strategies, some acute and chronic coronary syndrome (ACS and CCS) patients will suffer recurrent events (also called “extreme CV risk”). Recently new biochemical markers, such as uric acid (UA), lipoprotein A [Lp(a)] and several markers of inflammation, have been described to be associated with CV events recurrence. The SEcondary preVention and Extreme cardiovascular Risk Evaluation (SEVERE-1) study will accurately characterize extreme CV risk patients enrolled in cardiac rehabilitation (CR) programs. Aim. Our aims will be to describe the prevalence of extreme CV risk and its association with newly described biochemical CV risk factors. Aim Our aims will be to describe the prevalence of extreme CV risk and its association with newly described biochemical CV risk factors. Methods We will prospectively enrol 730 ACS/CCS patients at the beginning of a CR program. Extreme CV risk will be retrospectively defined as the presence of a previous (within 2 years) CV events in the patients’ clinical history. UA, Lp(a) and inflammatory markers (interleukin-6 and -18, tumor necrosis factor alpha, C-reactive protein, calprotectin and osteoprotegerin) will be assessed in ACS/CCS patients with extreme CV risk and compared with those without extreme CV risk but also with two control groups: 1180 hypertensives and 765 healthy subjects. The association between these biomarkers and extreme CV risk will be assessed with a multivariable model and two scoring systems will be created for an accurate identification of extreme CV risk patients. The first one will use only clinical variables while the second one will introduce the biochemical markers. Finally, by exome sequencing we will both evaluate polygenic risk score ability to predict recurrent events and perform mendellian randomization analysis on CV biomarkers. Conclusions Our study proposal was granted by the European Union PNRR M6/C2 call. With this study we will give definitive data on extreme CV risk prevalence rising attention on this condition and leading cardiologist to do a better diagnosis and to carry out a more intensive treatment optimization that will finally leads to a reduction of future ACS recurrence. This will be even more important for cardiologists working in CR that is a very important place for CV risk definition and therapies refinement.

10 August 2024 in Nutrition, Metabolism and Cardiovascular Diseases
Verified
Journal Article
Open access
CTChiara Tognola
Chiara Tognola
RIRita Cristina Myriam Intravaia
Rita Cristina Myriam Intravaia
ESEleonora Senini
Eleonora Senini
SPStefano Pezzoli
Stefano Pezzoli
ARAlfonso Riccio
Alfonso Riccio
AMALESSANDRO MALOBERTI
ALESSANDRO MALOBERTI
Patients with recent Acute Coronary Syndrome (ACS) or Chronic Coronary Syndrome (CCS) are all at very high CardioVascular (CV) risk. However, some of them are more likely to experience recurrent cardiovascular events (i.e extreme CV risk). A definition of which patients should be included in this category has been recently proposed by the European Society of Cardiology but data on its prevalence are still lacking, especially in the context of Cardiac Rehabilitation (CR). Furthermore, if this condition had an impact on the CR related functional improvement is not known. Our study has been designed to answer to both these questions. The study included 938 ACS/CCS patients who attended the CR program at the Niguarda Hospital (Milan). Extreme CV patients were defined as the presence of a previous CV events within 2 years or the presence of peripheral arteriopathy or the presence of a multivessel coronary involvement. Functional improvement was evaluated through 6-Minute Walking Test (6-MWT). As many as 26.9% of the patients had an extreme CV risk. They were older (67.8 ± 10.4 vs 64.1 ± 11.1 years; p ≤ 0.001), had a higher prevalence of CV risk factors and comorbidities and had a lower functional improvement during CR (102.9 ± 68.6 vs 138.1 ± 86.5 m; p ≤ 0.001). Extreme CV risk present a significant association with the 6-MWT results at multivariate analysis. Extreme CV risk is a very frequent condition among patients with ACS/CCS reaching the prevalence of 26.9%. Furthermore, being at extreme CV risk adversely affects the patient's functional improvement obtained during CR.